Laura M G Meems, Ingrid A Andersen, Shuchong Pan, Gail Harty, Yang Chen, Ye Zheng, Gerald E Harders, Tomoki Ichiki, Denise M Heublein, Seethalakshmi R Iyer, S Jeson Sangaralingham, Daniel J McCormick, John C Burnett
Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease...
April 2019: Hypertension